These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

351 related items for PubMed ID: 30520827

  • 41.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 42. The Pharmacogenetics of Tacrolimus in Corticosteroid-Sparse Pediatric and Adult Kidney Transplant Recipients.
    Madsen MJ, Bergmann TK, Brøsen K, Thiesson HC.
    Drugs R D; 2017 Jun; 17(2):279-286. PubMed ID: 28229376
    [Abstract] [Full Text] [Related]

  • 43. The impact of CYP3A4 and CYP3A5 genetic variations on tacrolimus treatment of living-donor Egyptian kidney transplanted patients.
    Wanas H, Kamel MH, William EA, Fayad T, Abdelfattah ME, Elbadawy HM, Mikhael ES.
    J Clin Lab Anal; 2023 Oct; 37(19-20):e24969. PubMed ID: 37789683
    [Abstract] [Full Text] [Related]

  • 44. Influence of cytochrome P450 3A5 polymorphisms on viral infection incidence in kidney transplant patients treated with tacrolimus.
    Hattori Y, Tanaka H, Teranishi J, Ishida H, Makiyama K, Miyajima E, Noguchi K, Kubota Y.
    Transplant Proc; 2014 Oct; 46(2):570-3. PubMed ID: 24656015
    [Abstract] [Full Text] [Related]

  • 45.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52. Personalized tacrolimus doses determined by CYP3A5 genotype for induction and maintenance phases of kidney transplantation.
    Vannaprasaht S, Reungjui S, Supanya D, Sirivongs D, Pongskul C, Avihingsanon Y, Tassaneeyakul W.
    Clin Ther; 2013 Nov; 35(11):1762-9. PubMed ID: 24120259
    [Abstract] [Full Text] [Related]

  • 53. Effects of Genetic Polymorphism in CYP3A4 and CYP3A5 Genes on Tacrolimus Dose Among Kidney Transplant Recipients.
    Yousef AM, Qosa H, Bulatova N, Abuhaliema A, Almadhoun H, Khayyat G, Olemat M.
    Iran J Kidney Dis; 2016 May; 10(3):156-63. PubMed ID: 27225724
    [Abstract] [Full Text] [Related]

  • 54. Influence of ABCB1, CYP3A4*18B and CYP3A5*3 polymorphisms on cyclosporine A pharmacokinetics in bone marrow transplant recipients.
    Qiu F, He XJ, Sun YX, Li-Ling J, Zhao LM.
    Pharmacol Rep; 2011 May; 63(3):815-25. PubMed ID: 21857093
    [Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57. [Cytochrome P450 3A polymorphism and its importance in cyclosporine and tacrolimus therapy in transplanted patients].
    Duricová J, Grundmann M.
    Ceska Slov Farm; 2007 Oct; 56(5):220-4. PubMed ID: 18064802
    [Abstract] [Full Text] [Related]

  • 58. Effect of Wuzhi preparations on tacrolimus in CYP3A5 expressers during the early period after transplantation: A real-life experience from heart transplant recipients.
    Zhou Y, Huang X, Liu L, Zeng F, Han Y, Zhang J, Zhou H, Zhang Y.
    Transpl Immunol; 2023 Feb; 76():101748. PubMed ID: 36423734
    [Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.